217 related articles for article (PubMed ID: 36744470)
1. Slower Calcium Handling Balances Faster Cross-Bridge Cycling in Human
Pioner JM; Vitale G; Steczina S; Langione M; Margara F; Santini L; Giardini F; Lazzeri E; Piroddi N; Scellini B; Palandri C; Schuldt M; Spinelli V; Girolami F; Mazzarotto F; van der Velden J; Cerbai E; Tesi C; Olivotto I; Bueno-Orovio A; Sacconi L; Coppini R; Ferrantini C; Regnier M; Poggesi C
Circ Res; 2023 Mar; 132(5):628-644. PubMed ID: 36744470
[TBL] [Abstract][Full Text] [Related]
2. Translational investigation of electrophysiology in hypertrophic cardiomyopathy.
Flenner F; Jungen C; Küpker N; Ibel A; Kruse M; Koivumäki JT; Rinas A; Zech ATL; Rhoden A; Wijnker PJM; Lemoine MD; Steenpass A; Girdauskas E; Eschenhagen T; Meyer C; van der Velden J; Patten-Hamel M; Christ T; Carrier L
J Mol Cell Cardiol; 2021 Aug; 157():77-89. PubMed ID: 33957110
[TBL] [Abstract][Full Text] [Related]
3. MYBPC3-c.772G>A mutation results in haploinsufficiency and altered myosin cycling kinetics in a patient induced stem cell derived cardiomyocyte model of hypertrophic cardiomyopathy.
Steczina S; Mohran S; Bailey LRJ; McMillen TS; Kooiker KB; Wood NB; Davis J; Previs MJ; Olivotto I; Pioner JM; Geeves MA; Poggesi C; Regnier M
J Mol Cell Cardiol; 2024 Jun; 191():27-39. PubMed ID: 38648963
[TBL] [Abstract][Full Text] [Related]
4.
Desai D; Song T; Singh RR; Baby A; McNamara J; Green L; Nabavizadeh P; Ericksen M; Bazrafshan S; Natesan S; Sadayappan S
bioRxiv; 2024 May; ():. PubMed ID: 38853909
[TBL] [Abstract][Full Text] [Related]
5. Contractile abnormalities and altered drug response in engineered heart tissue from Mybpc3-targeted knock-in mice.
Stöhr A; Friedrich FW; Flenner F; Geertz B; Eder A; Schaaf S; Hirt MN; Uebeler J; Schlossarek S; Carrier L; Hansen A; Eschenhagen T
J Mol Cell Cardiol; 2013 Oct; 63():189-98. PubMed ID: 23896226
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue.
Wijnker PJ; Friedrich FW; Dutsch A; Reischmann S; Eder A; Mannhardt I; Mearini G; Eschenhagen T; van der Velden J; Carrier L
J Mol Cell Cardiol; 2016 Aug; 97():82-92. PubMed ID: 27108529
[TBL] [Abstract][Full Text] [Related]
7. Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes.
Monteiro da Rocha A; Guerrero-Serna G; Helms A; Luzod C; Mironov S; Russell M; Jalife J; Day SM; Smith GD; Herron TJ
J Mol Cell Cardiol; 2016 Oct; 99():197-206. PubMed ID: 27620334
[TBL] [Abstract][Full Text] [Related]
8. Phosphomimetic cardiac myosin-binding protein C partially rescues a cardiomyopathy phenotype in murine engineered heart tissue.
Dutsch A; Wijnker PJM; Schlossarek S; Friedrich FW; Krämer E; Braren I; Hirt MN; Brenière-Letuffe D; Rhoden A; Mannhardt I; Eschenhagen T; Carrier L; Mearini G
Sci Rep; 2019 Dec; 9(1):18152. PubMed ID: 31796859
[TBL] [Abstract][Full Text] [Related]
9. Haploinsufficiency of MYBPC3 exacerbates the development of hypertrophic cardiomyopathy in heterozygous mice.
Barefield D; Kumar M; Gorham J; Seidman JG; Seidman CE; de Tombe PP; Sadayappan S
J Mol Cell Cardiol; 2015 Feb; 79():234-43. PubMed ID: 25463273
[TBL] [Abstract][Full Text] [Related]
10. Contractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic function.
van Dijk SJ; Paalberends ER; Najafi A; Michels M; Sadayappan S; Carrier L; Boontje NM; Kuster DW; van Slegtenhorst M; Dooijes D; dos Remedios C; ten Cate FJ; Stienen GJ; van der Velden J
Circ Heart Fail; 2012 Jan; 5(1):36-46. PubMed ID: 22178992
[TBL] [Abstract][Full Text] [Related]
11. Diltiazem prevents stress-induced contractile deficits in cardiomyocytes, but does not reverse the cardiomyopathy phenotype in Mybpc3-knock-in mice.
Flenner F; Geertz B; Reischmann-Düsener S; Weinberger F; Eschenhagen T; Carrier L; Friedrich FW
J Physiol; 2017 Jun; 595(12):3987-3999. PubMed ID: 28090637
[TBL] [Abstract][Full Text] [Related]
12. The mechanics of the heart: zooming in on hypertrophic cardiomyopathy and cMyBP-C.
Suay-Corredera C; Alegre-Cebollada J
FEBS Lett; 2022 Mar; 596(6):703-746. PubMed ID: 35224729
[TBL] [Abstract][Full Text] [Related]
13. Increased myofilament Ca2+ sensitivity and diastolic dysfunction as early consequences of Mybpc3 mutation in heterozygous knock-in mice.
Fraysse B; Weinberger F; Bardswell SC; Cuello F; Vignier N; Geertz B; Starbatty J; Krämer E; Coirault C; Eschenhagen T; Kentish JC; Avkiran M; Carrier L
J Mol Cell Cardiol; 2012 Jun; 52(6):1299-307. PubMed ID: 22465693
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ
Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529
[TBL] [Abstract][Full Text] [Related]
15. A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.
Seeger T; Shrestha R; Lam CK; Chen C; McKeithan WL; Lau E; Wnorowski A; McMullen G; Greenhaw M; Lee J; Oikonomopoulos A; Lee S; Yang H; Mercola M; Wheeler M; Ashley EA; Yang F; Karakikes I; Wu JC
Circulation; 2019 Feb; 139(6):799-811. PubMed ID: 30586709
[TBL] [Abstract][Full Text] [Related]
16. A hypertrophic cardiomyopathy-associated MYBPC3 mutation common in populations of South Asian descent causes contractile dysfunction.
Kuster DW; Govindan S; Springer TI; Martin JL; Finley NL; Sadayappan S
J Biol Chem; 2015 Feb; 290(9):5855-67. PubMed ID: 25583989
[TBL] [Abstract][Full Text] [Related]
17. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction.
van Dijk SJ; Dooijes D; dos Remedios C; Michels M; Lamers JM; Winegrad S; Schlossarek S; Carrier L; ten Cate FJ; Stienen GJ; van der Velden J
Circulation; 2009 Mar; 119(11):1473-83. PubMed ID: 19273718
[TBL] [Abstract][Full Text] [Related]
18. Variable cardiac myosin binding protein-C expression in the myofilaments due to MYBPC3 mutations in hypertrophic cardiomyopathy.
Parbhudayal RY; Garra AR; Götte MJW; Michels M; Pei J; Harakalova M; Asselbergs FW; van Rossum AC; van der Velden J; Kuster DWD
J Mol Cell Cardiol; 2018 Oct; 123():59-63. PubMed ID: 30170119
[TBL] [Abstract][Full Text] [Related]
19. Characterization of heterozygous and homozygous mouse models with the most common hypertrophic cardiomyopathy mutation MYBPC3
Hilderink S; Schuldt M; Goebel M; Jansen VJ; Manders E; Moorman S; Dorsch LM; van Steenbeek FG; van der Velden J; Kuster DWD
J Mol Cell Cardiol; 2023 Dec; 185():65-76. PubMed ID: 37844837
[TBL] [Abstract][Full Text] [Related]
20. Preserved cross-bridge kinetics in human hypertrophic cardiomyopathy patients with MYBPC3 mutations.
van Dijk SJ; Boontje NM; Heymans MW; Ten Cate FJ; Michels M; Dos Remedios C; Dooijes D; van Slegtenhorst MA; van der Velden J; Stienen GJ
Pflugers Arch; 2014 Aug; 466(8):1619-33. PubMed ID: 24186209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
